Browse the evidence

Mean arterial pressure (MAP) remains nearly constant between sodium intakes of 1,200 and 4,000 mg/d.

Practitioners may consider that moderate sodium intake does not significantly impact blood pressure.

The fraction of available calories from protein in the US food supply has decreased by ~1% since the early 1970s.

Awareness of changes in dietary composition over time is important for nutritional guidance.

More people around the world now have obesity than suffer from starvation.

This indicates a need for urgent public health interventions to address obesity.

The energy available in the food supply increased much more than population needs.

This suggests that dietary guidelines may need to be adjusted to account for excess energy availability.

Substantial investments in coordinated nutrition and agricultural research are needed to transform the food system.

This highlights the importance of policy and research in addressing obesity and food security.

The mean cumulative intervention costs for the intensive lifestyle intervention (ILI) were $11,275 per person, compared to $887 for standard diabetes support and education (DSE), resulting in ILI costing $6,666 more per person than DSE.

Practitioners should consider the higher costs associated with intensive lifestyle interventions compared to standard education.

The additional quality-adjusted life years (QALYs) gained by ILI were not statistically significant, with values of 0.17 and 0.16 measured by SF-6D and Feeling Thermometer, respectively.

The lack of statistically significant QALY gains suggests that intensive lifestyle interventions may not provide additional health benefits over standard education.

No significant findings emerged in men and women separately, in the African-American subset, or for the 8-10 week outcomes.

Results may not be generalizable across all demographics, highlighting the need for tailored approaches.

GLP-1RAs can induce gastric food retention, increasing the risk for pulmonary aspiration during anesthesia.

Clinicians should consider the risk of pulmonary aspiration when using GLP-1RAs in patients undergoing anesthesia.

Management of GLP-1RA adverse events lacks evidence-based support.

Healthcare providers should be cautious in applying management strategies for GLP-1RA adverse events due to the lack of evidence.

Rifampicin inhibits body weight gain in high-fat diet-fed mice.

Rifampicin may be considered as a potential treatment for obesity in high-fat diet contexts.

Rifampicin enhances lipolysis and suppresses lipogenesis in adipocytes.

Rifampicin may be useful in promoting fat loss by altering lipid metabolism.

The effects of rifampicin on obesity are mediated through Sirt6.

Targeting Sirt6 may enhance the effectiveness of rifampicin in obesity treatment.

Novel drug candidates like dual amylin and calcitonin receptor agonists (DACRAs) have insulin-sensitizing properties through a weight-independent action.

DACRAs may offer new treatment options for improving insulin sensitivity.

Mice receiving NN501 display a more gradual weight regain and no compensatory hyperphagic response after treatment cessation.

NN501 may help in maintaining weight loss without the rebound effects seen with other treatments.

GLP-1 receptor agonists (GLP-1RAs) may have neuroprotective and neurotrophic effects in ALS models.

GLP-1RAs may be considered for further investigation in ALS treatment.

Current clinical evidence does not demonstrate therapeutic benefit of GLP-1RAs in ALS.

Clinicians should be cautious in prescribing GLP-1RAs for ALS due to lack of evidence.

Obesity is characterized by adipose tissue dysfunction, insulin resistance, chronic low-grade inflammation, and gut microbiota dysbiosis.

Understanding these characteristics can help in developing targeted interventions for obesity.

Prior GLP-1 agonist use is not associated with in-hospital mortality in critically ill patients.

Clinicians may consider that prior GLP-1 agonist use does not adversely affect mortality in critically ill patients.

Prior GLP-1 agonist use is not associated with hospital length of stay in critically ill patients.

Clinicians may conclude that prior GLP-1 agonist use does not prolong hospital stays for critically ill patients.

Prior GLP-1 agonist use is not associated with ICU length of stay in critically ill patients.

Clinicians may determine that prior GLP-1 agonist use does not affect ICU length of stay for critically ill patients.

Greater achieved weight loss during the landmark period did not show a consistent association with lower post-landmark cardiovascular risk.

Weight loss alone may not be sufficient to reduce cardiovascular risk, emphasizing the importance of medication dosage.

Women's adjusted odds of diagnosis were far higher than men's (95% confidence interval 1.66-1.75).

Healthcare providers should consider gender disparities in obesity diagnosis when assessing patients.

Liraglutide did not have measurable effects on lean or bone tissue over the 18-day period.

Liraglutide may not affect muscle or bone mass in the short term.